Characterization of Ventricular Myocardium in Atrial Fibrillation: Looking Where the Light Is Best∗  by Sibley, Christopher T.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 7 , N O . 1 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 3 . 1 0 . 0 0 4E D I T O R I A L C OMM E N T
Characterization of Ventricular Myocardium in
Atrial Fibrillation: Looking Where the Light Is Best*
Christopher T. Sibley, MDPortland, OregonCatheter ablation has been established as an important
option in the treatment of patients with atrial ﬁbrilla-
tion. This therapy currently carries a class I indication in
patients with atrial ﬁbrillation who have failed to
respond to antiarrhythmic drug therapy and a class IIb
indication in patients with paroxysmal atrial ﬁbrillation
untreated with antiarrhythmic agents (1). Although the
evidence supports its role as an overall safe and effective
treatment for this common arrhythmia, serious com-
plications are not rare, and recurrent arrhythmia
necessitating repeat procedures is a frequent and vexing
problem (2). Tools to identify those more or less likely
to gain a lasting beneﬁt from this invasive procedure
would be a welcome addition to the ﬁeld.See page 1In this issue of iJACC, Neilan et al. (3) report the
association of cardiac extracellular volume (ECV)with
the risk of recurrent atrial ﬁbrillation after catheter
ablation. ECV is a quantitative correlate of diffuse
ﬁbrosis in the left ventricular myocardium derived
from contrast-enhanced cardiac magnetic resonance.
This marker has been histologically validated in a va-
riety of conditions and canbe relatively easilymeasured
during the course of cardiac magnetic resonance (4).
This study prospectively enrolled 145 patients
referred for cardiac magnetic resonance of the pul-
monary vein anatomy before planned catheter ablation
at a single center over 2.5 years. Patients were further
selected for an existing diagnosis of hypertension.
Those with diagnoses associated with a greater inci-
dence of replacement ﬁbrosis manifesting as overt late*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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diomyopathy, were excluded. Clinical risk factors and
echocardiographic measures of cardiac structure and
systolic and diastolic function were also obtained. The
data were analyzed to identify correlations between
ECV and other clinical predictors before ablation
and for prediction of adverse events after ablation in
univariate and multivariate models. The primary
outcome considered was clinically-apparent recurrent
atrial ﬁbrillation at a median of 18 months.
As expected, recurrent atrial ﬁbrillation after catheter
ablation was common in this population, with the
primary endpoint occurring in nearly one-third of all
patients. In the analysis of baseline clinical and
echocardiographic measures, ECV was signiﬁcantly
correlated with left atrial size, left ventricular mass, and
abnormal diastolic function.MeasuredECVwas similar
in a subset of patients imaged at basal, midventricular,
and apical slices, consistent with the hypothesis that
increased ﬁbrosis in these patients is a diffuse, global
process.Evidenceof focal injurywasquite rare,with only
2% demonstrating late gadolinium enhancement.
The primary ﬁnding of this study was the ability of
an increased ECV to predict recurrent atrial ﬁbrillation
(hazard ratio: 1.29; p< 0.0001). Therewas evidence of
a dose-effect relationship between increased ECV and
risk of recurrent atrial ﬁbrillation after ablation, with a
29% increase in the primary endpoint for every 10%
increase in ECV. This ﬁnding was entirely indepen-
dent of other clinical or imaging risk factors.
The authors also note a signiﬁcant association be-
tween ECV and overall cardiovascular events,
including heart failure and death. This combined
endpoint, however, was almost wholly driven by
recurrent arrhythmia, which accounted for 87% of
events during follow-up. The overall incidence of heart
failure and death was too low to permit truly mean-
ingful conclusions regarding ECV and such outcomes,
and this result should be interpreted with caution.
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13How could this information be useful in the
decision-making process when contemplating abla-
tion in a particular patient?Although the increased risk
of adverse events was highly signiﬁcant, the overall
magnitude of that risk is modest and certainly would
not warrant withholding this therapy simply on the
basis of an increased ECV. This information could be
of use in discussion of risks and beneﬁts while coun-
seling the patient about therapeutic options or poten-
tially in deciding to perform more extensive ablation
of the atrium over simpler pulmonary vein isolation.
What mechanism might plausibly connect the
ﬁnding of increased diffuse myocardial ﬁbrosis in
relatively remote ventricular myocardium with an
increased likelihood of atrial arrhythmia?The authors
speculate that ﬁbrosis results in abnormal diastolic
function by contributing to increased left ventricular
stiffness, hence resulting in elevated left atrial pres-
sure and, therefore, a greater propensity for future
atrial ﬁbrillation. This reasonable hypothesis is
circumstantially bolstered by the concomitant ﬁnding
of associations between ECV, atrial size, and
abnormal diastolic function by echocardiography. A
recent report found that invasively measured mean
left atrial pressure, at least in patients without marked
left atrial enlargement, predicted recurrence of atrial
ﬁbrillation (5).Were elevated left atrial pressure to be
the primary link between diffuse ﬁbrosis and atrial
ﬁbrillation, however, this might paradoxically
decrease the interest of the cardiac magnetic reso-
nance measurements described here. Catheter abla-
tion of atrial ﬁbrillation necessitates transseptal
puncture, and direct measurement of left atrial pres-
sure is a relatively trivial addition to the procedure.
A pathophysiological link between ECV and atrial
ﬁbrillation is likely to be more complex than a
straightforward matter of ventricular stiffness leading
to increased upstream chamber pressure. In theaforementioned study using invasive hemodynamic
measurements, left atrial pressure no longer predicted
recurrence of arrhythmia in patients withmoderate or
severe left atrial enlargement, suggesting that there
are other factors in play. It seems an attractive pos-
sibility that the diffuse increase in myocardial ﬁbrosis
in these patients, reﬂected in increased ECV, extends
to atrial as well as ventricular myocardium. Previous
investigations using both electroanatomic mapping
and imaging have established a link between atrial
scar and arrhythmia to support this possibility.
These hypothetical links would also help provide
an answer to an almost unavoidable question about
the choice of imaging targets in this study. Why
would one look at the ventricle to get answers about
an atrial problem? Visualization of replacement
ﬁbrosis as overt late gadolinium enhancement in the
atria is possible (6), but the atrial myocardium is too
thin to permit quantiﬁcation of diffuse ﬁbrosis as
performed with current methods. This calls to mind
the timeworn joke about a man found looking for
his lost keys under a street lamp. When asked where
he lost the keys, he points some distance away and
replies, “Over there, but the light is better here.”
The logic of this approach makes the best sense in
the setting of diffuse processesdpressure, ﬁbrosis,
or other factorsdaffecting both atria and ventricles.
Any new advanced imaging technique must ulti-
mately address the question: “who do I scan?” By iden-
tifying ECV as a unique and independent risk factor
for successful atrial ﬁbrillation ablation, Neilan et al. (3)
present a ﬁrst step toward incorporating this measure
into the evaluation of candidates for this procedure.
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